Eli Lilly Receives Upgraded Rating and Announces AI Partnership
BMO Capital reaffirmed an 'Outperform' rating on Eli Lilly with a $1,200 price target, citing growth in its incretin business and leadership in obesity treatment. The company also announced a partnership with NVIDIA to invest up to $1 billion in an AI co-innovation lab.